Xeris Biopharma Holdings, Inc. XERS Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s accounts receivable?
- Xeris Biopharma Holdings, Inc. (XERS) reported accounts receivable of $56.3M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s accounts receivable changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s accounts receivable increased by 21.5% year-over-year, from $46.33M to $56.3M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s accounts receivable?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s accounts receivable has grown at a 53.9% compound annual growth rate (CAGR), from $36.44M to $204.18M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.